Using blood tests to identify prostate cancer characteristics for better treatment predictions
Evaluating prostate cancer phenotype and genotype classification from circulating tumor DNA as biomarkers for predicting treatment outcomes
This study is looking at how bits of cancer DNA found in your blood can help doctors understand your prostate cancer better and predict how well different treatments might work for you, especially when regular biopsies are tough to do.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Fred Hutchinson Cancer Center NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project ID | NIH-10931638 on NIH RePORTER |
What this research studies
This research investigates how circulating tumor DNA from blood samples can be used to classify prostate cancer based on its genetic and phenotypic characteristics. By analyzing these biomarkers, the study aims to predict how well patients will respond to various treatments, particularly in cases where traditional biopsies are difficult or risky. The approach focuses on understanding tumor heterogeneity and resistance mechanisms that complicate treatment outcomes, potentially leading to more personalized and effective therapies for prostate cancer patients.
Who could benefit from this research
Good fit: Ideal candidates for this research include men diagnosed with prostate cancer, particularly those who have experienced treatment resistance or are considering new therapies.
Not a fit: Patients with early-stage prostate cancer who have not yet undergone treatment may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment strategies for prostate cancer, allowing for more accurate predictions of patient responses to therapies.
How similar studies have performed: Other research has shown promise in using circulating tumor DNA as a biomarker for various cancers, suggesting that this approach may yield valuable insights for prostate cancer as well.
Where this research is happening
Seattle, United States
- Fred Hutchinson Cancer Center — Seattle, United States (Active)
Researchers
- Principal investigator: Ha, Gavin — Fred Hutchinson Cancer Center
- Study coordinator: Ha, Gavin
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.